The earliest prospective, randomized double-blinded study to report on CV effects in T2D therapy is the University Group Diabetes Program conducted on 823 subjects assigned to the first-generation SU tolbutamide, lifestyle, insulin, or phenformin [19]. The gene discussed is INS; the disease is diabetes mellitus.